Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
暂无分享，去创建一个
P. Fasching | P. Neven | D. Slamon | S. Im | S. Chia | G. Jerusalem | Miguel Martín | G. Sonke | K. Petráková | T. Taran | J. Beck | G. Bianchi | A. Nusch | A. Chakravartty | J. P. Zarate | M. Laurentiis | L. Cruz-Merino | Craig Wang | U. Deore | J. P. Zárate